临床前CDMO研发筛选相关化合物如有产品调研服务, 请致函联系我们
客户展示
临床前CDMO研发化合物筛选
Etalocib
CAS号:161172-51-6
分子式: C33H33FO6 分子量: 544.61
产品形式: Free base
研发状态: Completed
研发用途: Carcinoma Non-Small-Cell Lung
研究机构: Eli Lilly and Company
研发日期: Sep-03
研发阶段: Phase 2
Etalocib(LY293111, VML295) is a leukotriene B4 receptor (LTB4R) antagonist that blocks activation of human neutrophils.
Bictegravir
中文名称:比克替拉韦
CAS号:1611493-60-7
分子式: C21H18F3N3O5 分子量: 449.38
产品形式: Free Base
研发状态: Recruiting
研发用途: HIV-1-infection
研究机构: Gilead Sciences
研发日期: December 13 2023
研发阶段: Phase 4
Bictegravir (GS-9883) is a novel, potent, once-daily, unboosted inhibitor of HIV-1 integrase.
BAY 1251152
CAS号:1610358-56-9
分子式: C19H18F2N4O2S 分子量: 404.43
产品形式: free base
研发状态: Completed
研发用途: Hematologic Neoplasms
研究机构: Bayer
研发日期: June 17 2016
研发阶段: Phase 1
BAY1251152 is a potent PTEFb/CDK9 inhibitor with an IC50 value of 3 nM for CDK9 and an at least 50-fold selectivity against other CDKs in enzymatic assays. BAY1251152 binds to and blocks the phosphorylation and kinase activity of CDK9, thereby preventing PTEFb-mediated activation of RNA Pol II and leading to the inhibition of gene transcription of various anti-apoptotic proteins.
Silodosin
中文名称:西洛多辛
CAS号:160970-54-7
分子式: C25H32F3N3O4 分子量: 495.53
产品形式: free base
研发状态: Completed
研发用途: Benign Prostatic Hyperplasia
研究机构: RECORDATI GROUP
研发日期: May-11
研发阶段: Phase 4
Silodosin (KAD 3213, KMD 3213) is a highly selective α1A-adrenoceptor antagonist, used in treatment of benign prostatic hyperplasia.
Deucravacitinib (BMS-986165)
CAS号:1609392-27-9
分子式: C20H19D3N8O3 分子量: 425.46
产品形式: free base
研发状态: Completed
研发用途: Healthy Participants
研究机构: Bristol-Myers Squibb
研发日期: December 18 2020
研发阶段: Phase 1
Deucravacitinib (BMS-986165) is a highly potent and selective allosteric inhibitor of Tyk2 with a Ki value of 0.02 nM for binding to the Tyk2 pseudokinase domain. It is highly selective against a panel of 265 kinases and pseudokinases.
AMG319
中文名称:(alphaS)-7-氟-alpha-甲基-N-9H-嘌呤-6-基-2-(2-吡啶基)-3-喹啉甲胺
CAS号:1608125-21-8
分子式: C21H16FN7 分子量: 385.40
产品形式: free base
研发状态: Terminated
研发用途: Human Papillomavirus (HPV); Positive or Negative Head and Neck Squamous Cell Carcinoma (HNSCC) of the Hypopharynx Oropharynx Oral Cavity Supraglottis or Larynx
研究机构: Cancer Research UK
研发日期: Oct-15
研发阶段: Phase 2
AMG319 is a potent and selective PI3Kδ inhibitor with IC50 of 18 nM, >47-fold selectivity over other PI3Ks. Phase 2.
我们的宗旨: 净化, 简洁, 高效Purifying, concise, efficient !我们的口号: 减少中间商赚差价!
即日起可免费注册成为会员, 建立企业产品库, 免费上传产品目录, 企业介绍等. 让你的产品直接呈现给客户.
试运营阶段,所有广告业务5折优惠
分类广告投放
依据化学成分的不同, 针对不同的企业和产品, 我们提供分类产品广告投放.客户展示
优秀企业推荐
